» Articles » PMID: 25634317

Papillomaviruses: Viral Evolution, Cancer and Evolutionary Medicine

Overview
Specialty General Medicine
Date 2015 Jan 31
PMID 25634317
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Papillomaviruses (PVs) are a numerous family of small dsDNA viruses infecting virtually all mammals. PVs cause infections without triggering a strong immune response, and natural infection provides only limited protection against reinfection. Most PVs are part and parcel of the skin microbiota. In some cases, infections by certain PVs take diverse clinical presentations from highly productive self-limited warts to invasive cancers. We propose PVs as an excellent model system to study the evolutionary interactions between the immune system and pathogens causing chronic infections: genotypically, PVs are very diverse, with hundreds of different genotypes infecting skin and mucosa; phenotypically, they display extremely broad gradients and trade-offs between key phenotypic traits, namely productivity, immunogenicity, prevalence, oncogenicity and clinical presentation. Public health interventions have been launched to decrease the burden of PV-associated cancers, including massive vaccination against the most oncogenic human PVs, as well as systematic screening for PV chronic anogenital infections. Anti-PVs vaccines elicit protection against infection, induce cross-protection against closely related viruses and result in herd immunity. However, our knowledge on the ecological and intrapatient dynamics of PV infections remains fragmentary. We still need to understand how the novel anthropogenic selection pressures posed by vaccination and screening will affect viral circulation and epidemiology. We present here an overview of PV evolution and the connection between PV genotypes and the phenotypic, clinical manifestations of the diseases they cause. This differential link between viral evolution and the gradient cancer-warts-asymptomatic infections makes PVs a privileged playground for evolutionary medicine research.

Citing Articles

Human Papilloma Virus Infection in Men: A Specific Human Virome or a Specific Pathology?.

culav I, Skerlev M, Starcevic L, Hrabac P, Ljubojevic Hadzavdic S, Beslic I Genes (Basel). 2025; 16(2).

PMID: 40004559 PMC: 11855728. DOI: 10.3390/genes16020230.


HPV Infection and Oral Microbiota: Interactions and Future Implications.

Xia Q, Pierson S Int J Mol Sci. 2025; 26(4).

PMID: 40003891 PMC: 11855562. DOI: 10.3390/ijms26041424.


Exploring the therapeutic potential of acorn extract in papillomavirus-induced lesions.

Medeiros-Fonseca B, Faustino-Rocha A, Pires M, Neuparth M, Vala H, Vasconcelos-Nobrega C Vet World. 2025; 17(11):2644-2658.

PMID: 39829663 PMC: 11736374. DOI: 10.14202/vetworld.2024.2644-2658.


The Natural History of Cervical Cancer and the Case for MicroRNAs: Is Human Papillomavirus Infection the Whole Story?.

Palomino-Vizcaino G, Banuelos-Villegas E, Alvarez-Salas L Int J Mol Sci. 2024; 25(23.

PMID: 39684702 PMC: 11641362. DOI: 10.3390/ijms252312991.


Why HPV16? Why, now, HPV42? How the discovery of HPV42 in rare cancers provides an opportunity to challenge our understanding about the transition between health and disease for common members of the healthy microbiota.

Bravo I, Belkhir S, Paget-Bailly P FEMS Microbiol Rev. 2024; 48(6).

PMID: 39562287 PMC: 11644485. DOI: 10.1093/femsre/fuae029.


References
1.
Ahola H, Stenlund A, Moreno-Lopez J, Pettersson U . Sequences of bovine papillomavirus type 1 DNA--functional and evolutionary implications. Nucleic Acids Res. 1983; 11(9):2639-50. PMC: 325914. DOI: 10.1093/nar/11.9.2639. View

2.
Tindle R . Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002; 2(1):59-65. DOI: 10.1038/nrc700. View

3.
Pfister H, Hettich I, RUNNE U, Gissmann L, Chilf G . Characterization of human papillomavirus type 13 from focal epithelial hyperplasia Heck lesions. J Virol. 1983; 47(2):363-6. PMC: 255268. DOI: 10.1128/JVI.47.2.363-366.1983. View

4.
Tabrizi S, Brotherton J, Kaldor J, Skinner S, Liu B, Bateson D . Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014; 14(10):958-66. DOI: 10.1016/S1473-3099(14)70841-2. View

5.
Quint W, Jenkins D, Molijn A, Struijk L, van de Sandt M, Doorbar J . One virus, one lesion--individual components of CIN lesions contain a specific HPV type. J Pathol. 2011; 227(1):62-71. DOI: 10.1002/path.3970. View